| 3.97 -0.29 (-6.81%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.55  |
1-year : | 9.4 |
| Resists | First : | 6.46 |
Second : | 8.05 |
| Pivot price | 5.91 |
|||
| Supports | First : | 3.9 |
Second : | 3.24 |
| MAs | MA(5) : | 4.69 |
MA(20) : | 6.2 |
| MA(100) : | 9.06 |
MA(250) : | 6.47  |
|
| MACD | MACD : | -1 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 2 |
D(3) : | 2.1 |
| RSI | RSI(14): 23.3 |
|||
| 52-week | High : | 16.34 | Low : | 2.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARMP ] has closed above bottom band by 3.3%. Bollinger Bands are 11.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.33 - 4.37 | 4.37 - 4.39 |
| Low: | 3.82 - 3.87 | 3.87 - 3.9 |
| Close: | 3.91 - 3.99 | 3.99 - 4.04 |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Mon, 13 Jul 2026
Armata receives FDA agreement on pediatric study plan for AP-SA02 - Investing.com UK
Mon, 13 Jul 2026
FDA backs pediatric study framework for Armata’s Staph infection therapy AP-SA02 - Stock Titan
Fri, 10 Jul 2026
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Mon, 29 Jun 2026
Armata Pharmaceuticals, Inc.(NYSEAM: ARMP) added to Russell 2500 Growth Benchmark - marketscreener.com
Wed, 24 Jun 2026
Armata Pharmaceuticals (ARMP) assigns Gilmer to governance committee with $5,000 retainer - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|